Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04082650
Other study ID # VDPI
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 15, 2020
Est. completion date March 10, 2024

Study information

Verified date July 2022
Source Women's Hospital School Of Medicine Zhejiang University
Contact Dan Zhang, M.D. Ph.D.
Phone 86-0571-87061501-1008
Email zhangdan@zju.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This multicenter double-blinded placebo-controlled randomised trial aims to evaluate the effectiveness of vitamin D supplementation prior to IVF on the live birth rate in women with PCOS. Women with PCOS scheduled for IVF will be enrolled. Eligible participants will be randomised 1:1 to receive oral capsules of 4000IU vitamin D per day or placebo for around 12 weeks until the day of triggering.


Description:

Polycystic ovary syndrome (PCOS) is one of the leading causes of female infertility, affecting around 5% of women with a child-bearing age in China. Vitamin D insufficiency is common in women with PCOS and is associated with lower live birth rates in these women. However, evidence regarding the effectiveness of vitamin D treatment in women with PCOS is inconclusive. This multicenter double-blinded placebo-controlled randomised trial aims to evaluate the effectiveness of vitamin D supplementation prior to IVF on the live birth rate in women with PCOS. The investigators plan to enroll women with PCOS scheduled for IVF. Eligible participants will be randomised 1:1 to receive oral capsules of 4000IU vitamin D per day or placebo for around 12 weeks until the day of triggering. All IVF procedures will be carried out following a routine method in each center. Women will be followed up until six months after randomisation for those who fail to get pregnant after the completion of the first embryo transfer or delivery for those who get pregnant after the first embryo transfer. The primary outcome is live birth after the first embryo transfer. Primary analysis will be by intention-to-treat analysis. The investigators plan to recruit 860 women to demonstrate women treated with vitamin D have a higher live birth rate than those treated with placebo (48% versus 38%), accounting for 10% loss to follow-up with a significance level at 0.05 and a power of 80%.


Recruitment information / eligibility

Status Recruiting
Enrollment 860
Est. completion date March 10, 2024
Est. primary completion date February 2, 2023
Accepts healthy volunteers No
Gender Female
Age group 20 Years to 42 Years
Eligibility Inclusion criteria 1. Women aged 20 to 42 years old; 2. Diagnosed with PCOS (Rotterdam Criteria); 3. Scheduled for IVF; 4. Written informed consent. Exclusion criteria 1. Women who had three or more failed IVF cycles; 2. Women scheduled for preimplantation genetic testing; 3. Known Vitamin D allergy; 4. Women with a history of chronic absorption syndrome or bile dysplasia, or parathyroid dysfunction, or kidney stones, or blood Calcium ion concentration greater than 2.6mmol/L (normal value 2.25 - 2.75mmol/L (9 to 11mg/dl), or hyperphosphataemia (1.61mmol/L), or metabolic-related bone disease, or chronic diseases that may cause bone abnormalities (liver and kidney insufficiency); 5. Women receiving treatments for tuberculosis, convulsions, and epilepsy because medications treating these diseases may affect the metabolism of vitamin D. 6. Women undergoing an IVF treatment with donor oocytes.

Study Design


Intervention

Drug:
vitamin D
4000IU per day
Other:
Placebo
The same doses with vitamin D

Locations

Country Name City State
China Peking University Third Hospital Beijing Beijing
China Women's Hospital, Zhejiang University School of Medicine Hangzhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
Women's Hospital School Of Medicine Zhejiang University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants with live birth The primary outcome is live birth after the first embryo transfer. Live birth is defined as the delivery of at least one baby after 24 weeks of gestation that exhibits any sign of life. 1 day after delivery
Secondary Number of Participants with Cumulative live birth Cumulative live birth: defined as live birth resulting from pregnancies that occur within 6 months after randomization. 6 months after randomization of the last participant
Secondary Number of Participants with Clinical pregnancy Clinical pregnancy: defined as at least one gestational sac on ultrasound at around 7 weeks' gestation with the detection of heart beat activity after the completion of the first embryo transfer; 4 weeks after embryo transfer
Secondary birth weight Weight of newborns at delivery. The day of delivery
Secondary Number of Participants with miscarriage miscarriage was defined as a positive pregnancy test but no detectable heart rate before 24 weeks' gestation after the completion of the first transfer; 24 gestational weeks in maximum
Secondary Number of Participants with Ongoing pregnancy defined as pregnancy with detectable heart rate at 12 weeks' gestation or beyond after the completion of the first transfer at 12 weeks' gestation
Secondary Number of Participants with Biochemical pregnancy defined with a positive pregnancy test 2 weeks after embryo transfer
Secondary Number of Participants with Ectopic pregnancy defined as embryo implanted at any site other than the endometrial lining of the uterus cavity after the completion of the first transfer 4 weeks after embryo transfer
Secondary Number of Participants with Ovarian hyperstimulation syndrome defined according to the Golan criteria. Moderate OHSS is diagnosed by the presence of ascites on ultrasonography in addition to abdominal distension and discomfort with or without nausea, vomiting and/or diarrhea. Severe OHSS is diagnosed when there is clinical evidence of ascites and/or hydrothorax or breathing difficulties with or without hemoconcentration, coagulation abnormalities and diminished renal function. From the day of oocyte retrieval to two weeks after embryo transfer
Secondary Number of available embryos for transfer non 5 days after oocyte retrieval
Secondary Number of Participants with Pre-eclampsia defined as the development of gestational hypertension with proteinuria (=300 mg/24-hour urine collection or 30 mg/dL in single urine sample) of new onset after 20 weeks of gestation after the completion of the first transfer 20 weeks of gestation till delivery
Secondary Number of Participants with Gestational hypertension defined as the development of blood pressure greater than 140/90 mmHg after pregnancy without proteinuria or other signs of preeclampsia after the completion of the first transfer; 20 weeks of gestation till delivery
Secondary Number of Participants with Premature rupture of membrane PROM was defined as rupture of the amniotic membranes before the onset of labor including PROM at term and preterm PROM. The day of delivery
Secondary Number of Participants with Postpartum hemorrhage defined as the loss of 500 ml of blood or more after completion of the third stage of labor after the completion of the first transfer 1 day after delivery
Secondary Number of Participants with Preterm delivery Defined as delivery of a fetus at less than 37 and more than 28 weeks' gestational age after the completion of the first transfer 1 day after delivery
Secondary Number of Participants with Gestational diabetes mellitus defined as carbohydrate intolerance of variable severity with onset or first recognition during pregnancy as determined from the diagnosis in the obstetrical medical record Up to ten months once the participants get pregnancy
Secondary Number of Participants with Placenta previa defined as a placenta that is implanted over or very close to the internal cervical orifice after 24 weeks of gestation
Secondary Number of Participants with Stillbirth defined as the absence of signs of life at or after birth after the completion of the first transfer 1 day after delivery
Secondary Apgar score non 1 minute or 5 minutes after delivery
Secondary Serum Vitamin D binding protein, glucose, insulin, Calcium ion concentration non The day of oocyte retrieval
Secondary Serum vitamin levels Serum vitamin levels at the triggering day One day before oocyte retrieval
See also
  Status Clinical Trial Phase
Completed NCT03142633 - MicroRNA as Biomarkers for Development of Metabolic Syndrome in Women With Polycystic Ovary Syndrome
Completed NCT06158932 - A Single Group Study to Evaluate the Effects of a Myo-Inositol and D-Chiro Inositol Supplement on Symptoms Associated With Polycystic Ovary Syndrome and Hormone Imbalance N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Active, not recruiting NCT02500147 - Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS) Phase 4
Completed NCT04932070 - Berberine and Polycystic Ovary Syndrome N/A
Suspended NCT03652987 - Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS)
Completed NCT03480022 - Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS Phase 3
Active, not recruiting NCT03043924 - Functional Study of the Hypothalamus in Magnetic Resonance Imaging (MRI) in Polycystic Ovary Syndrome (PCOS) N/A
Completed NCT05246306 - Aerobic Capacity and Physical Fitness Level of Adolescents With PCOS
Completed NCT05981742 - Effects of Combined Metformin and Cabergoline in Comparison With Metformin Only Therapy on Ovarian and Hormonal Activities in Iraqi Patients With PCOS Phase 2
Completed NCT05702957 - Letrozole vs Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovarian Syndrome Phase 2/Phase 3
Completed NCT05029492 - Effect of Visceral Manipulation on PCOS N/A
Completed NCT02924025 - Motivational Interviewing as an Intervention for PCOS N/A
Not yet recruiting NCT02255578 - Endobarrier Treatment in Women With PCOS Phase 3
Withdrawn NCT01638988 - Clomifene Citrate Versus Metformin in First-line Treatment of Infertility in Patients With Polycystic Ovary Syndrome and a Resistance to Insulin Phase 3
Completed NCT02098668 - Mathematical Model for the Human Menstrual Cycle, Endocrinological Diseases and Fertility Treatment-PAEON N/A
Not yet recruiting NCT00883259 - Metformin and Gestational Diabetes in High-risk Patients: a RCTs Phase 4
Completed NCT01462864 - Development of a Structured Education Programme for Women With Polycystic Ovary Syndrome N/A
Recruiting NCT01431352 - Letrozole Versus Chinese Herbal Medicine on Polycystic Ovary Syndrome (PCOS) N/A
Completed NCT00989781 - Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome N/A